Attitudes of men in an Australian male tolerance study towards microbicide use

Sexual Health

Volumn 5, Issue 3, 2008, Pages 273-278

  Holmes, Wendy R ^a   Maher, Lisa ^b   Rosenthal, Susan L ^c  

^a MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Acceptability; Sexuality

Indexed keywords

PLACEBO; VIVAGEL;

ADULT; AGED; ARTICLE; ATTITUDE TO SEXUALITY; AUSTRALIA; CLINICAL TRIAL; CONDOM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG USE; GEL; HUMAN; LUBRICATION; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEMI STRUCTURED INTERVIEW; SEXUAL BEHAVIOR; SEXUALITY; SEXUALLY TRANSMITTED DISEASE;

ADMINISTRATION, INTRAVAGINAL; ADULT; AGED; ANTI-INFECTIVE AGENTS; AUSTRALIA; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; PATIENT ACCEPTANCE OF HEALTH CARE; POLYLYSINE; QUESTIONNAIRES; SAFE SEX; SEXUALLY TRANSMITTED DISEASES, BACTERIAL; SPERMATOCIDAL AGENTS;

EID: 49449107558     PISSN: 14485028     EISSN: None     Source Type: Journal    
DOI: 10.1071/SH07093     Document Type: Article

References (35)

1. Holmes KK, Levine R, Weaver M. Effectiveness of condoms in preventing sexually transmitted infections. Bull World Health Organ 2004; 82: 454-64.
2. Wald A, Langenberg AG, Krantz E, Douglas JM Jr, Handsfield HH, DiCarlo RP, et al. The relationship between condom use and herpes simplex virus acquisition. Ann Intern Med 2005; 143: 707-13.
3. Winer RL, Hughes JP, Feng Q, O'Reilly S, Kiviat NB, Holmes KK, et al. Condom use and the risk of genital human papillomavirus infection in young women. N Engl J Med 2006; 354: 2645-54. doi: 10.1056/NEJMoa053284
4. Miller WC, Zenilman JM. Epidemiology of chlamydial infection, gonorrhea, and trichomoniasis in the United States - 2005. Infect Dis Clin North Am 2005; 19: 281-96. doi: 10.1016/j.idc.2005.04.001
5. Brown AE, Sadler KE, Tomkins SE, McGarrigle CA, LaMontagne DS, Goldberg D, et al. Recent trends in HIV and other STIs in the United Kingdom: data to the end of 2002. Sex Transm Infect 2004; 80: 159-66. doi: 10.1136/sti.2004.009571
6. De Visser R. Delayed application of condoms, withdrawal and negotiation of safer sex among heterosexual young adults. AIDS Care 2004; 16: 315-22. doi: 10.1080/09540120410001665321
7. Flood M. Lads in Latex? Why young heterosexual men don't use condoms. Impact 2003; 4, 10-11. Available online at: http://www.xyonline.net/ Ladsinlatex.shtml [verified 1 August 2007].
8. Smith AMA, Jolley D, Hocking J, Benton K, Gerofi J. Factors affecting men's liking of condoms they have used. Int J STD AIDS 1999; 10: 258-62. doi: 10.1258/0956462991913907
9. Lim MS, Hellard ME, Aitken CK, Hocking JS. Sexual-risk behaviour, self-perceived risk and knowledge of sexually transmissible infections among young Australians attending a music festival. Sex Health 2007; 4: 51-6. doi: 10.1071/SH06031
10. Mantell JE, Dworkin SL, Exner TM, Hoffman S, Smit JA, Susser I. The promises and limitations of female-initiated methods of HIV/STI protection. Soc Sci Med 2006; 63: 1998-2009. doi: 10.1016/ j.socscimed.2006.05.008
11. Bentley ME, Fullem AM, Tolley EE, Kelly CW, Jogelkar N, Srirak N, et al. Acceptability of a microbicides among women and their partners in a 4-country phase I trial. Am J Public Health 2004; 94: 1159-64.
12. Bentley ME, Morrow KM, Fullem A, Chesney MA, Horton SD, Rosenberg Z, et al. Acceptability of a novel vaginal microbicide during a safety trial among low-risk women. Fam Plann Perspect 2000; 32: 184-8. doi: 10.2307/2648235
13. Morrow K, Rosen R, Richter L, Emans A, Forbes A, Day J, et al. The acceptability of an investigational vaginal microbicide, PRO 2000 gel, among women in a phase I clinical trial. J Women's Health 2003; 12: 655-66. doi: 10.1089/154099903322404302
14. Coggins C, Blanchard K, Friedland B. Men's attitudes towards a potential vaginal microbicide in Zimbabwe, Mexico and the USA. Reprod Health Matters 2000; 8: 132-41. doi: 10.1016/S0968-8080(00)90015-6
15. Carballo-Diéguez A, Balán IC, Morrow K, Rosen R, Mantell JE, Gai F, et al. Acceptability of tenofovir gel as a vaginal microbicide byUSmale participants in a Phase I clinical trial (HPTN 050). AIDS Care 2007; 19: 1026-31. doi: 10.1080/09540120701294237
16. Farr G, Gabelnick H, Sturgen K, Dorflinger L. Contraceptive efficacy and acceptability of the female condom. Am J Public Health 1994; 84: 1960-4.
17. Widman L, Welsh DP, McNulty JK, Little KC. Sexual communication and contraceptive use in adolescent dating couples. J Adolesc Health 2006; 39: 893-9. doi: 10.1016/j.jadohealth.2006.06.003
18. Frank ML, Poindexter AN, Cox CA, Bateman L. A cross-sectional survey of condom use in conjunction with other contraceptive methods. Women Health 1995; 23: 31-46. doi: 10.1300/J013v23n02_03
19. Severy LJ, Tolley E, Woodsong C, Guest G. A framework for examining the sustained acceptability of microbicides. AIDS Behav 2005; 9: 121-31. doi: 10.1007/s10461-005-1687-y
20. Ritchie J, Spencer L. Qualitative data analysis for applied policy research. In: Bryman A, Burgess RG (eds). Analyzing qualitative data. New York: Routledge; 1994. pp. 173-194.
21. Baleta A. A second chance for microbicides. Lancet 2007; 370: 17-8. doi: 10.1016/S0140-6736(07)61029-0
22. Foss AM, Vickerman PT, Heise L, Watts CH. Shifts in condom use following microbicide introduction: should we be concerned? AIDS 2003; 17: 1227-37. doi: 10.1097/00002030-200305230-00015
23. Imrie J, Elford J, Kippax S, Hart G. Biomedical HIV prevention - and social science. Lancet 2007; 370: 10-1. doi: 10.1016/S0140-6736(07)61026- 5
24. Cassell M, Halperin DT, Shelton JD, Stanton D. Risk compensation: the Achilles' heel of innovation in HIV prevention. BMJ 2006; 332: 605-7. doi: 10.1136/bmj.332.7541.605
25. Smith AMA, Jolley D, Hocking J, Benton K, Gero J. Does additional lubrication affect condom slippage and breakage? Int J STD AIDS 1998; 9: 330-5. doi: 10.1258/0956462981922359
26. Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet 2007; 369: 787-97. doi: 10.1016/S0140-6736(07)60202-5
27. Keogh LA. Understandings of the 'natural' body: a comparison of the views of users and providers of emergency contraception. Sex Health 2005; 2: 109-15. doi: 10.1071/SH04023
28. Braunstein S, van de Wijgert J. Preferences and practices related to vaginal lubrication: implications for microbicide acceptability and clinical testing. J Women's Health 2005; 14: 424-33.
29. Messiah A, Blin P, Fiche V. Sexual repertoires of heterosexuals: implications for HIV/sexually transmitted disease risk and prevention. The ACSF Group. AIDS 1995; 9: 1357-65. doi: 10.1097/00002030-199512000-00009
30. de Visser RO, Smith AM, Rissel CE, Richters J, Grulich AE. Sex in Australia: heterosexual experience and recent heterosexual encounters among a representative sample of adults. Aust N Z J Public Health 2003; 27: 146-54. doi: 10.1111/j.1467-842X.2003.tb00802.x
31. Mosher WD, Chandra A, Jones J. Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2002. CDC Advance data from health and vital statistics. 2005; 362. Available online at: http://www.cdc.gov/nchs/data/ad/ad362.pdf. [verified 26 July 2007].
32. Halperin DT. Heterosexual anal intercourse: prevalence, cultural factors, and HIV infection and other health risks. Part I. AIDS Patient Care STDS. 1999; 13: 717-30.
33. Richters J, Grulich AE, de Visser RO, Smith AM, Rissel CE. Sex in Australia: autoerotic, esoteric and other sexual practices engaged in by a representative sample of adults. Aust N Z J Public Health 2003; 27: 180-90. doi: 10.1111/j.1467-842X.2003.tb00806.x
34. Leone P, Warren T, Hamed K, Fife K, Wald A. Famciclovir reduces viral mucosal shedding in HSV-seropositive persons. Sex Transm Dis 2007; 34: 900-7.
35. Tolley EE, Severy LJ. Integrating behavioral and social science research into microbicide clinical trials: challenges and opportunities. Am J Public Health 2006; 96: 79-83. doi: 10.2105/AJPH.2004.043471